STAT+: Hims & Hers will stop selling compounded version of Novo’s obesity pill

Hims & Hers, a telehealth company, has decided to stop selling its compounded version of Novo Nordisk's weight-loss drug, Wegovy, following legal challenges and an ongoing investigation by the FDA. The company had been marketing this alternative for €41, which drew significant criticism from Novo Nordisk, the Danish pharmaceutical company that developed Wegovy. Novo Nordisk has initiated legal action against Hims & Hers for allegedly infringing on a key patent related to Wegovy, describing Hims & Hers' product as an “untested knockoff” and accusing the company of “illegal mass compounding” (Stat News, Euronews). The chief counsel of Novo Nordisk has warned that telehealth companies and compounding pharmacies producing similar versions of Wegovy should be “very, very much on notice” regarding the legal implications of their actions. Novo Nordisk has expressed concerns over the safety and efficacy of the unregulated compounded product, emphasizing the potential risks to patient safety associated with such alternatives (Stat News). The situation has raised broader concerns within the pharmaceutical and telehealth industries regarding the legality and ethical implications of producing compounded medications that mimic established drugs. The legal battle between Novo Nordisk and Hims & Hers underscores the tension between established pharmaceutical companies and emerging telehealth providers in the rapidly evolving landscape of weight-loss treatments (Stat News, Financial Times). The outcome of this lawsuit could have significant repercussions for both companies and the compounding pharmacy sector as a whole. Hims & Hers' decision to abandon the sale of its copycat weight-loss drug highlights the challenges faced by companies in the burgeoning telehealth market and reflects the scrutiny from regulatory bodies regarding compounded medications (Financial Times).